argenx halts Phase 3 UNITY trial for efgartigimod futility

argenx SE will discontinue the Phase 3 UNITY study of efgartigimod SC in Sjögren’s disease after an IDMC recommended stopping for futility at interim, with safety consistent with prior profile.